Objective To analyze the clinical effect of urinary kallikrein combined with tirofiban in acute cerebral infarction with super thrombolytic time window,and observe the changes of serum inflammatory factor index interleukin(IL)-6 and tumor necrosis factor α(TNF-α)levels.Methods A total of 86 patients with acute cerebral infarction with super thrombolytic time window admitted to cerebrovascular disease ward of Puyang Oilfield General Hospital from May 2021 to May 2022 were randomly divided into an observation group and a control group,with 43 cases in each group.The control group was treated with urinary kallikrein,and the observation group was treated with urinary kallikrein combined with tirofiban.The neurological deficits,daily living activities and the levels of inflammatory factors and the occurrence of adverse reactions were compared between the two groups.Results At 14 and 30 days after treatment,the National Institutes of Health stroke scale(NIHSS)score of the observation group was lower than that of the control group,and the Barthel index score was higher than that of the control group,with statistical significance(P＜0.05).14 days after treatment,the levels of IL-6 and TNF-α in the observation group were lower than those in the control group,and the differences were statistically significant(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion For patients with acute cerebral infarction whose super thrombolytic time window has been exceeded,the treatment of urinary kallikrein and tirofiban can improve the clinical efficacy,reduce the inflammatory response,and do not increase the adverse reactions.
Acute cerebral infarctionTirofibanUrinary kallikreinSuper thrombolytic time window
NETL
NSTL
万方数据
